Clinical Trials Logo

Clinical Trial Summary

This study is based on the hypothesis that MRI could make it possible to non-invasively detect these amyloid deposits at the level of the wrist using parametric sequences known as T1 mapping, in the form of an extension of T1 in the wrists. areas where amyloid deposits are found in the wrist.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05150353
Study type Interventional
Source Ramsay Générale de Santé
Contact Jean-François Oudet
Phone 0683346567
Email jf.oudet@ecten.eu
Status Recruiting
Phase N/A
Start date January 24, 2020
Completion date April 24, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05200897 - Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With Insomnia N/A
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Recruiting NCT05138848 - Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease N/A
Recruiting NCT06186167 - Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting NCT06048601 - 18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis N/A
Active, not recruiting NCT04027712 - Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Not yet recruiting NCT04760171 - Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Active, not recruiting NCT03431896 - Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Withdrawn NCT04984330 - Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease Early Phase 1
Recruiting NCT04270175 - Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Phase 2